Table 5.
Ovarian cancer member characteristics by stage, diagnosed 2016–2020 (N = 723)
| Stage | I | II | III | IV |
|---|---|---|---|---|
| n (%)a, b | 247 (34.2%) | 79 (10.9%) | 270 (37.3%) | 127 (17.6%) |
| Age, mean (SD), yearsb | 53.5 (14.6) | 58.5 (12.1) | 59.6 (13.3) | 61.5 (11.3) |
| Female Gender, n (%)b | 247 (100.0%) | 79 (100.0%) | 270 (100.0%) | 127 (100.0%) |
| Insurance Type, n (%)a, b | ||||
| Commercial | 153 (61.9%) | 46 (58.2%) | 131 (48.5%) | 71 (55.9%) |
| Medicaid | 15 (6.1%) | 8 (10.1%) | 10 (3.7%) | 4 (3.2%) |
| Medicare Advantage | 57 (23.1%) | 24 (30.4%) | 99 (36.7%) | 46 (36.2%) |
| Multiplec | 0 (0.0%) | 0 (0.0%) | 2 (0.7%) | 0 (0.0%) |
| Unknown | 22 (8.9%) | 1 (1.3%) | 28 (10.4%) | 6 (4.7%) |
| Geographic Region, n (%)a, b | ||||
| Midwest | 105 (42.5%) | 25 (31.7%) | 115 (42.6%) | 45 (35.4%) |
| Northeast | 92 (37.3%) | 27 (34.2%) | 78 (28.9%) | 34 (26.8%) |
| South | 26 (10.5%) | 15 (19.0%) | 47 (17.4%) | 23 (18.1%) |
| West | 18 (7.3%) | 8 (10.1%) | 26 (9.6%) | 17 (13.4%) |
| Unknown | 6 (2.4%) | 4 (5.1%) | 4 (1.5%) | 8 (6.3%) |
| CCI, mean (SD)d | 0.7 (1.1) | 0.9 (1.4) | 1.0 (1.5) | 1.2 (1.6) |
| CCI, n (%)a, d | ||||
| 0 | 73 (64.0%) | 20 (57.1%) | 68 (57.6%) | 32 (44.4%) |
| 1 | 23 (20.2%) | 8 (22.9%) | 21 (17.8%) | 16 (22.2%) |
| 2 | 10 (8.8%) | 4 (11.4%) | 14 (11.9%) | 14 (19.4%) |
| ≥ 3 | 8 (7.0%) | 3 (8.6%) | 15 (12.7%) | 10 (13.9%) |
Charlson Comorbidity Index; SD Standard deviation
a Percentages may not total to 100% due to rounding
b Demographics were calculated at the time of cancer diagnosis
c Individuals had insurance eligibility from multiple types during this period
d CCI was calculated among subjects with 6 months of continuous insurance eligibility prior to their cancer diagnosis